Heise Marta, Jarzemski Piotr, Bąk Aneta, Junkiert-Czarnecka Anna, Pilarska-Deltow Maria, Haus Olga
Department of Clinical Genetics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruñ, Poland.
Department of Urology, Jan Biziel University Hospital in Bydgoszcz, Poland.
Pol J Pathol. 2019;70(2):127-133. doi: 10.5114/pjp.2019.87103.
We tested the association between HOXB13 G84E (rs138213197) germline mutation and PC risk in Polish men. DNA from 103 consecutive, newly diagnosed patients hospitalised because of PC and DNA from 103 men: volunteers, healthy at the time of the study. The G84E mutation was genotyped using Sanger sequencing. The HOXB13 G84E germline mutation was detected in 2.9% of PC men (3/103) and not detected in any healthy man. Two mutation carriers originated from two of 25 families fulfilling hereditary prostate cancer criteria (HPC) and one mutation carrier from one family among 78 families without HPC (PC frequency: 8% vs. 1.3%, OR = 6.70, p = 0.13). In two of three mutation carriers, disease was detected above 60 years of age. There was a trend for a lower probability of 5-year survival in patients with G84E than in patients without it (66.7% vs. 94.0%, p = 0.08). The HOXB13 G84E germline mutation is associated with increased prostate cancer risk in Polish men, with hereditary form of the disease, and probably with older age at PC onset (> 60 years of age) and shorter survival. However, it is not associated with PSA level, or PC stage or grade at the time of diagnosis.
我们检测了波兰男性中HOXB13 G84E(rs138213197)种系突变与前列腺癌风险之间的关联。收集了103例因前列腺癌连续住院的新诊断患者的DNA,以及103名男性志愿者(研究时健康)的DNA。采用桑格测序法对G84E突变进行基因分型。在2.9%的前列腺癌男性患者(3/103)中检测到HOXB13 G84E种系突变,而在任何健康男性中均未检测到。两名突变携带者来自满足遗传性前列腺癌标准(HPC)的25个家族中的两个家族,一名突变携带者来自78个无HPC家族中的一个家族(前列腺癌发生率:8%对1.3%,OR = 6.70,p = 0.13)。在三名突变携带者中的两名中,疾病在60岁以上被检测到。G84E患者5年生存率低于无该突变患者的概率有一定趋势(66.7%对94.0%,p = 0.08)。HOXB13 G84E种系突变与波兰男性前列腺癌风险增加、疾病的遗传形式相关,可能还与前列腺癌发病年龄较大(>60岁)和生存期较短有关。然而,它与前列腺特异性抗原水平、诊断时的前列腺癌分期或分级无关。